This study characterizes the effects of a novel LKB1 isoform generated by CRISPR/Cas9 in A549 and its impact on metabolic targets and cellular pathways, showing the feasibility of using NHEJ repair mediated by CRISPR to rescue the expression of tumor suppressors. This evidence concerns the gene STK11 and neoplasm.